We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Cardiology

Journal Scan / Research · January 06, 2021

Adjunctive Cilostazol May Aid in the Prevention of Ischemic Vascular Events in Clopidogrel-Treated T2D Patients

Journal of the American Heart Association


Additional Info

Journal of the American Heart Association
Efficacy and Safety of Adjunctive Cilostazol to Clopidogrel-Treated Diabetic Patients With Symptomatic Lower Extremity Artery Disease in the Prevention of Ischemic Vascular Events
J Am Heart Assoc 2020 Dec 17;[EPub Ahead of Print], K Kalantzi, N Tentolouris, AJ Melidonis, S Papadaki, M Peroulis, KA Amantos, G Andreopoulos, GI Bellos, D Boutel, M Bristianou, D Chrisis, NA Dimitsikoglou, J Doupis, C Georgopoulou, SA Gkintikas, S Iraklianou, Κ Kanellas, K Kotsa, T Koufakis, M Kouroglou, AG Koutsovasilis, L Lanaras, E Liouri, C Lixouriotis, A Lykoudi, E Mandalaki, E Papageorgiou, N Papanas, S Rigas, MI Stamatelatou, I Triantafyllidis, A Trikkalinou, AN Tsouka, O Zacharopoulou, C Zoupas, I Tsolakis, AD Tselepis

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading